• Private equity stake: TPG and Temasek diluted approximately 12.6% of their 43% combined holding for about ₹2,000 crore. Both funds have a standard 90-day lock-in period and are expected to unload any further holdings gradually over the long term.
• Promoter shareholding target: The promoter family currently holds around 32% of the company and intends to gradually increase its stake to north of 40% as opportunities arise.
• Regulatory tariff impact: Proposed price caps and room-rate limits will not affect the ophthalmology chain, as it operates entirely on a day-care model with 0% revenue derived from overnight patient stays.
• Subsidized care initiatives: Dr. Agarwal's already conducts free cataract surgeries in rural areas via its Eye Research Center under the government's National Program for Control of Blindness, operating it as a charitable venture excluded from company revenues.